NPC(SH:600713) Zheng Quan Zhi Xing·2025-05-21 09:29Core Viewpoint - Nanjing Pharmaceutical Co., Ltd. has approved the use of up to 700 million yuan of temporarily idle raised funds for cash management, focusing on low-risk, high-liquidity principal-protected financial products [1] Group 1: Cash Management Implementation - The company and its subsidiaries have utilized 142 million yuan to purchase a structured deposit product from Ping An Bank, which is 100% principal-protected and linked to exchange rates, with a 14-day cycle [2] - As of March 19, 2025, the company redeemed part of the financial product, recovering 2 million yuan in principal and earning 0.066 million yuan in interest, which has been returned to the dedicated fundraising account [2] - On April 21, 2025, the company redeemed another portion, recovering 3 million yuan in principal and earning 0.69808 million yuan in interest, also returned to the dedicated fundraising account [3] Group 2: Total Redemption and Earnings - By May 20, 2025, the company redeemed a total of 58 million yuan in principal from the financial products, with total earnings amounting to 1.49874 million yuan [3] - The company has a total cash management limit of 700 million yuan, with 584 million yuan already utilized and 116 million yuan remaining [5] - The highest single-day investment amount in the last 12 months was 700 million yuan, representing 10.24% of the audited net assets for the past year [5]